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Abstract
Background: Disease caused by the dengue virus (DENV) is a significant cause of morbidity throughout the world. Although
prior research has focused on the association of specific DENV serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) with the
development of severe outcomes such as dengue hemorrhagic fever and dengue shock syndrome, relatively little work has
correlated other clinical manifestations with a particular DENV serotype. The goal of this study was to estimate and compare
the prevalence of non-hemorrhagic clinical manifestations of DENV infection by serotype.
Methodology and Principal Findings: Between the years 2005–2010, individuals with febrile disease from Peru, Bolivia,
Ecuador, and Paraguay were enrolled in an outpatient passive surveillance study. Detailed information regarding clinical
signs and symptoms, as well as demographic information, was collected. DENV infection was confirmed in patient sera with
polyclonal antibodies in a culture-based immunofluorescence assay, and the infecting serotype was determined by
serotype-specific monoclonal antibodies. Differences in the prevalence of individual and organ-system manifestations were
compared across DENV serotypes. One thousand seven hundred and sixteen individuals were identified as being infected
with DENV-1 (39.8%), DENV-2 (4.3%), DENV-3 (41.5%), or DENV-4 (14.4%). When all four DENV serotypes were compared
with each other, individuals infected with DENV-3 had a higher prevalence of musculoskeletal and gastrointestinal
manifestations, and individuals infected with DENV-4 had a higher prevalence of respiratory and cutaneous manifestations.
Conclusions/Significance: Specific clinical manifestations, as well as groups of clinical manifestations, are often
overrepresented by an individual DENV serotype.
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Introduction
The world is experiencing a rapid increase in dengue virus
(DENV) infections with an estimated 50 million people infected
annually, and nearly two-fifths of the world’s population is living in
areas considered high-risk for infection [1]. DENVs are divided
into four antigenically distinct serotypes (DENV-1, DENV-2,
DENV-3, and DENV-4), and human infection may be asymp-
tomatic or manifest as dengue fever, dengue hemorrhagic fever
(DHF), or dengue shock syndrome (DSS). Despite widespread
eradication of the mosquito vector Aedes aegypti in the 1950s, the
continent of South America has once again become an epicenter
of this spreading epidemic with nearly a five-fold increase in the
incidence of detectable dengue infection over the last three
decades and a concomitant expansion of the number of circulating
serotypes [2]. For instance, Bolivia experienced its first re-
emergent dengue fever case in 1987, followed by Paraguay and
Ecuador in 1988, and Peru in 1990 [3]. At that time, only DENV-
1 was present. Today, all four of these countries have experienced
the introduction of multiple serotypes.
The most common form of symptomatic DENV infection,
dengue fever, often presents with fever, headache, and severe bone
and joint pains [4]. DENV infection also commonly affects a wide
array of organ systems, including the dermatologic, neurologic,
respiratory, and gastrointestinal systems [5]. Less commonly
described manifestations include those affecting the cardiac [6],
lymphoreticular [6], renal [6], and ocular [7] systems.
Risk factors for the severe manifestations of DHF and DSS have
been attributed to a multitude of factors, including secondary
versus primary infection [8], specific serotype [9] or genotype [10],
gender [11], and age [12]. While much attention has focused on
the factors causing severe and hemorrhagic disease, much less has
been dedicated to comparing differences in specific clinical
manifestations by DENV serotype. Only a handful of reports
www.plosntds.org 1 May 2012 | Volume 6 | Issue 5 | e1638[13,14,15,16,17,18,19,20,21,22] (Table 1) have used serotype-
confirmed DENV infection to compare non-hemorrhagic clinical
manifestations between serotypes, and there is heterogeneity
across these studies. Many of these studies lacked a large sample
size, restricted their analyses to inpatients, did not examine all four
DENV serotypes, or did not recruit both children and adults.
The goal of the current cross-sectional study was to estimate and
compare the prevalence of specific clinical signs and symptoms by
DENV serotype among a large number of individuals participat-
ing in a passive clinic-based surveillance system for febrile illness
across western South America.
Methods
Study Population
In 2000, the Naval Medical Research Center Detachment
(NMRCD) initiated an outpatient passive surveillance system to
detect acute febrile disease in Peru and Bolivia [23]. In 2001 and
2005, study sites in Ecuador and Paraguay were added,
respectively. All recruitment was performed at outpatient clinics
(Figure 1) by local doctors trained in the protocol and
recruitment specifications. A site utilizing medical technicians
(Iquitos, Peru) instead of medical doctors for data collection was
excluded from our analysis. Participants eligible for recruitment:
were five years of age or older, had a temperature $38uC, had no
obvious focus of infection, and were able to sign a consent form.
Participants younger than age 18 provided written assent following
written consent from their parent or guardian. Participants
included in this study were recruited between the dates of January
1, 2005 and August 20, 2010.
Ethics Statement
Study protocols (NMRCD.2000.0006 [Peru], NMRCD.2000.
0008 [Bolivia], NMRCD.2001. 0002 [Ecuador], and NMRCD.
2005.0008 [Paraguay]) were approved by the Naval Medical
Research Center Institutional Review Board (Bethesda, MD) in
compliance with all U.S. Federal regulations governing the
protection of human subjects. In addition, study protocols were
reviewed and approved by health authorities in Peru (Direccio ´n
General de Epidemio ´loga and Instituto Nacional de Salud),
Bolivia (Servicio Departamental de Salud, Santa Cruz, and
Colegio Me ´dico de Santa Cruz), Ecuador (Ministerio de Salud
Publica and Escuela de Sanidad Naval in Guayaquil), and
Paraguay (Ministerio de Salud y Bienestar Social and Comite ´d e
E ´tica de Asociacion Rayos de Sol).
Data and Sample Collection
A complete history and physical examination was performed on
every participant by a study doctor at each outpatient site. Each
doctor was provided with the same data collection form that
possessed an extensive list of signs and symptoms. The form also
contained basic demographic data such as age, gender, and town
of residence, as well as day of illness onset. All information used in
this study was collected at the initial visit. A blood sample was
obtained by venipuncture from the arm, using standard methods.
Laboratory Methods
DENV isolation was performed on acute serum samples taken
from patients seven days or fewer following the onset of illness on
the first day they sought medical care in our study. Sera were
inoculated on Aedes albopictus C6/36 and African green monkey
kidney (Vero) cells. Upon observation of cytopathic effect or after
ten days, the cells were collected by centrifugation and examined
by indirect immunofluorescence assay (IFA) using screening
dengue polyclonal antisera. To identify the specific DENV
serotype, serotype-specific monoclonal antibodies were generated
using hybridomas obtained from the Centers of Disease Control
and Prevention. On the acute sera, IgM and IgG titers were
measured using a previously described enzyme-linked immuno-
sorbent assay [23]. IgM/IgG ratios were then calculated and
compared with a ratio known to discriminate between primary
and secondary infections, similar to an approach used by others
[24].
Clinical Definitions
Participants with serotype-specific dengue infection were
defined as having sera with DENV confirmed by culture/IFA.
In order to take a broader look at how often certain groups of
manifestations were affected by specific serotypes, the following
clinical manifestation groups were constructed: ‘‘Constitutional
manifestations’’ was defined as having malaise, prostration,
headache, or retro-orbital pain; ‘‘Respiratory manifestations’’
was defined as having a cough, dyspnea, rhinorrhea, pharyngeal
congestion, wheezing, cyanosis, or rhonchi; ‘‘Gastrointestinal
manifestations’’ was defined as having abdominal pain, abdominal
distension, diarrhea, nausea, vomiting, ascites, hepatomegaly,
splenomegaly, or jaundice; ‘‘Musculoskeletal manifestations’’ was
defined as having bone pain, myalgia, or joint pain (a combined
endpoint of arthritis, arthalgia, and incapacity of joint function);
‘‘Cutaneous manifestations’’ was defined as having a maculopap-
ular rash, central erythema, distal erythema, facial erythema,
vesicles, or subcutaneous nodules; ‘‘Neurological manifestations’’
was defined as having seizures, neck stiffness, impaired mental
status, or a focal neurological deficit. For a participant to be noted
as being affected by a certain manifestation category, they needed
to have at least one specific manifestation from that category. Vital
signs were not collected.
Statistical Analysis
The objective of this analysis was to compare the prevalence of
clinical manifestations across individuals with the four different
DENV serotypes. Overall, there were 1938 individuals presenting
Author Summary
Dengue virus (DENV) causes disease in millions of people
annually and disproportionately affects those in the
developing world. DENVs may be divided into four
serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and a
geographical region may be affected by one or more
DENV serotypes simultaneously. Infection with DENV may
cause life-threatening disease such as dengue hemorrhag-
ic fever (DHF) or dengue shock syndrome (DSS), but more
often causes less severe manifestations affecting a wide
range of organs. Although many previous reports have
explored the role of the different DENV serotypes in the
development of severe manifestations, little attention has
focused on the relative role of each DENV serotype in the
development of cutaneous, respiratory, gastrointestinal,
musculoskeletal, and neurological manifestations. We
recruited a large group of participants from four countries
in South America to compare the prevalence of more than
30 manifestations among the four different DENV sero-
types. We found that certain DENV serotypes were often
associated with a higher prevalence of a certain manifes-
tation (e.g., DENV-3 and diarrhea) or manifestation group
(e.g., DENV-4 and cutaneous manifestations).
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www.plosntds.org 3 May 2012 | Volume 6 | Issue 5 | e1638with febrile illness at clinics in western South America and
diagnosed with one of four DENV serotypes. Individuals with
missing information on sex (n=1) and date of illness (n=5) were
excluded from the analysis.There were 216 individuals withmissing
data on one or more sign or symptom. These individuals did not
differ from the remaining individuals with respect to age, sex,
location, or DENV serotype and therefore were excluded from the
analysis. Because differences in demographic factors could con-
found the primary comparisons of the prevalence of manifestations
between DENV serotypes, demographic variables such as age, sex,
city, and year of diagnosis were assessed. Age was categorized into
deciles of #10 years, 11–20 years, 21–30 years, 31–40 years, 41–50
years,51–60years,.60years.Time sinceillness onsetwasbased on
the interval between the clinic visit and a participant’s self-reported
first occurrence of febrile illness. This measure was defined in days
and treated as continuous in the analysis. Country and city of
residence was categorized as Peru (La Merced, Puerto Maldonado,
Piura, Tumbes, Yurimaguas), Bolivia (Concepcion, Magdalena,
Santa Cruz, Villa Tunari), Ecuador (Guayaquil, Puyo), and
Paraguay (Asuncion, Central, Ciudad del Este, Encarnacion,
Filadelfia). Year of diagnosis was treated as continuous.
Contingency tables were created to assess the prevalence of
clinical manifestations and demographic variables with serotype-
specific DENV infection. Differences in the distribution of
demographic variables across DENV serotype were evaluated
using Pearson’s chi-square statistic or Wilcoxon Rank Sum test for
categorical or continuous data, respectively.
Given the high prevalence of clinical manifestations in this study
population, odds ratios as a measure of association calculated
using logistic regression could have overestimated the strength of
the association [25]. Therefore, prevalence ratios (PR) were
estimated using Poisson regression with robust variance [26].
Based on the laboratory-confirmed DENV serotype, a dummy
variable was created that classified each individual as having been
infected with a given DENV serotype versus infection with another
DENV serotype (e.g., DENV-1 vs. non-DENV-1). All models
compared the prevalence of a given manifestation among
individuals with a given serotype-specific DENV infection against
those infected with the other three DENV serotypes and were
adjusted by age, sex, city, days of illness at presentation, DENV
infection status (primary versus secondary), and year of diagnosis.
Lastly, given the large number of comparisons across multiple
clinical manifestations within a given group of individuals infected
with a specific DENV serotype, a more conservative p-value
estimate of 0.005 was used as a cut-off for statistical significance
based on the Bonferroni correction for multiple comparisons. All
analyses were performed using STATA 11.0 (STATACORP;
College Station, TX).
Results
Distribution of Demographic Factors and DENV Serotype
Between January 1, 2005, and August, 20, 2010, 1, 716
individuals were identified as infected with a DENV with the
following breakdown: DENV-1, 39.8%; DENV- 2, 4.3%; DENV-
3, 41.5%; or DENV-4, 14.4% (Table 2). The median age of the
sample was 29 years (IQR: 20, 41). While there was no significant
difference in the mean age by DENV serotype, individuals with
DENV-1 were generally younger (,20 years of age). A higher
proportion of men were diagnosed with DENV-2.
Comparing the frequency of serotype-specific DENV infection
by year of diagnosis, a majority of DENV-1 and DENV-4
Figure 1. Location of participant recruitment sites.
doi:10.1371/journal.pntd.0001638.g001
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www.plosntds.org 4 May 2012 | Volume 6 | Issue 5 | e1638Table 2. Association of demographic variables and dengue serotype.
Total
N(%)
(N=1,716)
DENV-1
(n=683) (39.8%)
DENV-2
(n=74) (4.3%)
DENV-3
(n=712) (41.5%)
DENV-4
(n=247) (14.4%)
N(%) N(%) N(%) N(%)
Age (by decile):
#10 74 (4.3) 42 (6.2) 2 (2.7) 19 (2.7) 11 (4.5)
11–20 390 (22.7) 171 (25.0) 14 (18.9) 150 (21.1) 55 (22.3)
21–30 466 (27.2) 193 (28.3) 20 (27.0) 196 (27.5) 57 (23.1)
31–40 334 (19.5) 110 (16.1) 17 (22.9) 154 (21.6) 53 (21.5)
41–50 271 (15.8) 98 (14.3) 15 (20.3) 120 (16.9) 38 (15.4)
51–60 127 (7.4) 43 (6.3) 5 (6.8) 53 (7.4) 26 (10.5)
.60 54 (3.1) 26 (3.8) 1 (1.4) 20 (2.8) 7 (2.7)
Sex:
Male 833 (48.5) 320 (46.9) 47 (63.5) 352 (49.4) 114 (46.2)
Female 883 (51.5) 363 (53.1) 27 (36.5) 360 (50.6) 133 (53.8)
Time since symptom onset (days):
0 79 (4.6) 26 (3.8) 4 (5.4) 40 (5.6) 9 (3.7)
1 373 (21.7) 146 (21.4) 16 (21.6) 165 (23.2) 46 (18.7)
2 469 (27.3) 184 (26.9) 21 (28.3) 190 (26.8) 74 (29.9)
3 392 (22.8) 160 (23.4) 14 (18.9) 149 (20.9) 69 (27.9)
4 189 (11.1) 77 (11.3) 7 (9.5) 78 (10.9) 27 (10.9)
5 91 (5.3) 32 (4.7) 5 (6.7) 45 (6.4) 9 (3.6)
6 41 (2.4) 16 (2.4) 3 (4.1) 17 (2.4) 5 (2.1)
7 58 (3.4) 27 (3.9) 3 (4.1) 21 (2.9) 7 (2.8)
Unknown 24 (1.4) 15 (2.2) 1 (1.4) 7 (0.9) 1 (0.4)
Infection type:
Primary 792 (46.2) 408 (59.7) 13 (17.6) 315 (44.2) 56 (22.7)
Secondary 809 (47.1) 225 (32.9) 50 (67.5) 356 (50.0) 178 (72.0)
Unknown 115 (6.7) 50 (7.4) 11 (14.9) 41 (5.8) 13 (5.3)
Peru: 1,339 (78.0) 520 (38.8) 46 (3.4) 527 (39.4) 246 (18.4)
La Merced 118 (8.9) 0 (0) 0 (0) 72 (13.6) 46 (18.6)
Puerto Maldonado 353 (26.4) 20 (3.9) 46 (100) 287 (54.5) 0 (0)
Piura 226 (16.8) 213 (40.9) 0 (0) 3 (0.6) 10 (4.1)
Tumbes 311 (23.2) 269 (51.7) 0 (0) 0 (0) 42 (17.1)
Yurimaguas 331 (24.7) 18 (3.5) 0 (0) 165 (31.3) 148 (60.2)
Bolivia: 217 (12.7) 98 (45.2) 24 (11.0) 95 (43.8) 0 (0)
Concepcion 51 (23.5) 36 (36.7) 3 (12.5) 12 (12.6) 0 (0)
Magdalena 1 (0.5) 0 (0) 0 (0) 1 (1.1) 0 (0)
Santa Cruz 89 (41.0) 49 (50.0) 21 (87.5) 19 (20.0) 0 (0)
Villa Tunari 76 (35.0) 13 (13.3) 0 (0) 63 (66.3) 0 (0)
Ecuador: 26 (1.5) 13 (50.0) 0 (0) 12 (46.2) 1 (3.8)
Guayaquil 17 (65.4) 4 (30.8) 0 (0) 12 (100) 1 (100)
Puyo 9 (34.6) 9 (69.2) 0 (0) 0 (0) 0 (0)
Paraguay: 134 (7.8) 52 (38.8) 4 (3.0) 78 (58.2) 0 (0)
Asuncion 43 (32.1) 9 (17.3) 2 (50.0) 32 (41.0) 0 (0)
Central 32 (23.9) 0 (0) 0 (0) 32 (41.0) 0 (0)
Ciudad de Este 50 (37.3) 42 (80.8) 2 (50.0) 6 (7.7) 0 (0)
Encarnacion 2 (1.5) 0 (0) 0 (0) 2 (2.6) 0 (0)
Filadelfia 7 (5.2) 1 (1.9) 0 (0) 6 (7.7) 0 (0)
Year of Diagnosis:
2005 137 (7.9) 33 (4.8) 0 (0) 104 (14.6) 0 (0)
Clinical Manifestations by Dengue Virus Serotype
www.plosntds.org 5 May 2012 | Volume 6 | Issue 5 | e1638infections occurred in 2009 and 2010, while a majority of DENV-
2 infections occurred in 2007. Lastly, a higher prevalence of
DENV-3 was observed between 2005–2007.
The majority of DENV-infected patients were from Peru
(78.0%), followed by Bolivia (12.7%), Paraguay (7.8%), and
Ecuador (1.5%). There was significant heterogeneity in the
prevalence of dengue serotype by study site.
In Peru, Piura and Tumbes had the highest prevalence of
DENV-1 as compared to other DENV serotypes (p,0.001 for
comparison with other sites in Peru) while all DENV-2 infections
and a majority of DENV-3 infections were detected in Puerto
Maldonado. Additionally, Yurimaguas had the highest prevalence
of DENV-4 as compared to other DENV serotypes (p=0.002 for
comparison with other sites in Peru). In Bolivia, Santa Cruz had
the highest prevalence of DENV-1 and DENV-2 (p=0.001 for
both), and Villa Tunari had the highest prevalence of DENV-3
(p=0.001). In Ecuador, all individuals infected with DENV-3 and
DENV-4 were diagnosed in Guayaquil, and a higher proportion of
individuals infected with DENV-1 were diagnosed in Puyo
(p=0.01). In Paraguay, a higher percentage of DENV-1 cases
were diagnosed in Ciudad del Este (p=0.002); furthermore, a
higher percentage of DENV-3 infections were diagnosed in the
two cities of Asuncion and Central, Paraguay (p=0.01 for both).
Individuals with DENV-2 and DENV-4 infections were more
likely to have been previously exposed to DENV (p,0.001 for
both). Conversely, individuals with DENV-1 were less likely to
have been previously exposed to DENV (p,0.001).
Prevalence of Clinical Manifestation by DENV Serotype
Constitutional manifestations. A majority of individuals
with DENV infection had manifestations in this category (99.5%)
at the time of their clinic visit (Tables 3 and S1). As compared to
individuals infected with other DENV serotypes, individuals
with DENV-1 were less likely to report malaise (p,0.001). As
compared to individuals with DENV infection of other serotypes,
individuals with DENV-2 were more likely to report malaise
(p,0.001). As compared to individuals with DENV infection of
other serotypes, individuals with DENV-3 had a higher prevalence
of malaise (p,0.001), headache (p=0.002), and prostration
(p,0.001). Conversely, individuals with DENV-3 had a lower
prevalence of retro-orbital pain (p=0.001). Lastly, individuals with
DENV-4, as compared to those with DENV infection of other
serotypes, were less likely to report prostration (p,0.001).
Respiratory manifestations. The prevalence of respiratory
manifestations in this sample was 30.8% (Tables 3 and S1).
Individuals infected with DENV-1 had a higher prevalence of
rhinorrhea compared to individuals infected with other DENV
serotypes (p,0.001). Individuals infected with DENV-3 had a
lower prevalence of rhinorrhea (p=0.003) compared to
individuals infected with other DENV serotypes. Individuals
infected with DENV-4 had a higher prevalence of pharyngeal
congestion (p=0.001) compared to individuals infected with other
DENV serotypes.
Gastrointestinal manifestations. Greater than half of the
participants had gastrointestinal manifestations (70.2%) (Tables 3
and S1). Compared to individuals infected with other DENV
serotypes, a lower prevalence of gastrointestinal manifestations was
found in those infected with DENV-1 (p=0.003), characterized by
a lower prevalence of abdominal pain (p,0.001) and diarrhea
(p=0.001). Relative to those infected with other DENV serotypes,
individuals infected with DENV-3 were more likely to report
gastrointestinal manifestations (p,0.001), characterized by a
higher prevalence of nausea (p,0.001), abdominal pain
(p,0.001), vomiting (p=0.005), and diarrhea (p,0.001). Among
those infected with DENV-4, a lower prevalence of gastrointestinal
manifestations in general (p=0.001) characterized by a lower
prevalence of nausea (p=0.001), vomiting (p,0.001), and
diarrhea (p=0.002) were found compared to those infected with
the other three DENV serotypes.
Musculoskeletal manifestations. Musculoskeletal manife-
stations were reported by a majority of individuals in this sample
(94.3%) (Tables 3 and S1). Individuals with DENV-1 were more
likely to report bone pain (p,0.001), but less likely to report joint
pain (p,0.001) compared with those infected with other DENV
serotypes. Individuals with DENV-2 were less likely to report
myalgia (p=0.004) than those infected with other DENV serotypes.
Compared with those infected with other DENV serotypes,
individuals infected with DENV-3 were more likely to report joint
paint (p,0.001) and myalgia (p=0.001). Lastly, individuals with
DENV-4 were less likely to report bone pain (p,0.001) compared
to those infected with other DENV serotypes.
Cutaneous manifestations. Cutaneous manifestations were
reported by 21.9% of the sample (Tables 3 and S1). Individuals
with DENV-3 were less likely to have cutaneous manifestations
(p,0.001) when compared to those infected with other serotypes.
The lower prevalence of cutaneous manifestations among those
with DENV-3 was characterized by a lower prevalence of central
erythema (p,0.001), facial erythema (p,0.001), distal erythema
(p=0.001), and maculopapular rash (p=0.004). Conversely,
compared with those infected with other DENV serotypes, the
prevalence of cutaneous manifestations was higher among
individuals with DENV-4 (p,0.001) and was characterized by a
higher prevalence of central erythema (p,0.001), distal erythema
(p,0.001), facial erythema (p,0.001), and maculopapular rash
(p,0.001).
Table 2. Cont.
Total
N(%)
(N=1,716)
DENV-1
(n=683) (39.8%)
DENV-2
(n=74) (4.3%)
DENV-3
(n=712) (41.5%)
DENV-4
(n=247) (14.4%)
N(%) N(%) N(%) N(%)
2006 94 (5.5) 21 (3.1) 1 (1.4) 70 (9.9) 2 (0.8)
2007 248 (14.4) 9 (1.3) 54 (72.9) 185 (25.9) 0 (0)
2008 142 (8.3) 29 (4.3) 1 (1.4) 61 (8.7) 51 (20.7)
2009 449 (26.2) 258 (37.7) 6 (8.1) 121 (16.9) 64 (25.9)
2010 646 (37.7) 333 (48.8) 12 (16.2) 171 (24.0) 130 (52.6)
doi:10.1371/journal.pntd.0001638.t002
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were reported by 2.7% of the sample (Tables 3 and S1). No
difference in neurological manifestations was observed by DENV
serotype.
Discussion
This cross-sectional study, conducted as part of an on-going
passive surveillance screening program across a wide geographic
region of western South America, identified distinct differences in
the prevalence of clinical manifestations by DENV serotype.
Individuals with DENV-3 had a higher prevalence of musculo-
skeletal and gastrointestinal manifestations, whereas individuals
with DENV-4 infection had a higher prevalence of cutaneous and
respiratory manifestations. The recent introduction and establish-
ment of multiple co-circulating serotypes of DENV in various
regions of the world, including South America, has heightened the
importance of understanding and characterizing the role each
serotype plays in the clinical outcome of infection.
Constitutional manifestations are well-known to DENV infec-
tion, but are also present in many other diseases. Unlike any study
to date, our study uniquely demonstrated a significantly higher
frequency of headache and prostration with DENV-3 infection
when compared with infection with the other DENV serotypes. In
addition, the higher prevalence of malaise with DENV-2 and
DENV-3 compared with the other DENV serotypes was also a
novel finding.
DENVs have been detected and isolated in respiratory
specimens of both the upper and lower respiratory tract from
individuals with confirmed dengue fever or DHF [27,28]. Only a
handful of studies have examined DENV serotype differences in
respiratory manifestations. One study from Thailand [19] noted
no difference between all four serotypes when assessing for the
presence of pleural effusion, although a higher pleural effusion
index was found in DENV-2 compared with DENV-1. Our study
did not specifically examine pleural effusions. A study from
Taiwan [14] comparing only two DENV serotypes showed a
common respiratory endpoint (combining cough, rhinorrhea,
nasal stuffiness, or sore throat) was more prevalent in DENV-3
than DENV-2. In contrast, we looked at all four DENV serotypes
and found two respiratory correlations not reported previously in
the literature: an increased prevalence of rhinorrhea with DENV-
1 infection and an increased prevalence of pharyngeal congestion
with DENV-4 infection.
DENV infection can result in a wide array of gastrointestinal
manifestations and can often be mistaken for other entities,
including acute appendicitis, acute cholecystitis, and diffuse
peritonitis [29,30]. Most previous studies examining the common
symptoms associated with gastrointestinal illness such as nausea,
vomiting, diarrhea, and abdominal pain showed no association
with specific dengue serotype [13,15,16]. However, a study from
India [22] with all four DENV serotypes demonstrated more
abdominal pain in those infected with DENV2 and one study from
Martinique with only two serotypes noted a higher prevalence of
unspecified gastrointestinal manifestations among those with
DENV-2 as compared to DENV-4 [17]. Our findings of a higher
prevalence of gastrointestinal manifestations, specifically symp-
toms such as nausea, abdominal pain, vomiting and diarrhea
among those infected with DENV-3 compared to the other three
DENV serotypes has not been reported prior to this. Regarding
gastrointestinal signs, a pediatric study from Thailand [20]
reported a higher prevalence of hepatomegaly among those
infected with DENV-2 and DENV-3 and a study from India [22]
found a higher prevalence with DENV-2, whereas others studies
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Two prior studies [14,19] examining ascites observed a higher
prevalence among individuals with DENV-3 (compared to
DENV-2) and DENV-2 (compared to the other three DENV
serotypes). In our population, we did not find any correlation
between a specific DENV serotype and the signs of abdominal
distension, hepatomegaly, splenomegaly, jaundice, or ascites.
DF is nicknamed ‘‘breakbone fever’’ and it was therefore not
surprising that the three individual constituents of the ‘‘musculo-
skeletal manifestation’’ category–muscle, bone, and joint pains–
were each reported by over two-thirds of all participants surveyed.
Our statistically significant finding of DENV-3 causing more
myalgia was also found in a study from Taiwan [14] that
examined only two serotypes (DENV-2 and DENV-3). In
addition, we found that infection with DENV-3 predisposed to
more joint pain, a novel finding. In comparison, a study from
Nicaragua [18] demonstrated more arthralgia in infection with
DENV-2 than DENV-1. A study from another group in Peru [16]
found significantly different amounts of bone pain in the three
serotypes they investigated, with DENV-2 having the most,
DENV-1 having the second most, and DENV-3 having the least.
This is in contrast with our results, which showed a greater
percentage of bone pain with DENV-1 infection.
Skin findings associated with DENV infection are well-
described [31] and may be useful in distinguishing DENV
infection from other endemic causes of febrile disease [32].
Classically, flushing or a macular erythematous rash affecting the
face, neck, and chest is noted within the first 48 hours of symptom
onset, later evolving to a more maculopapular rash. Individuals
infected with DENV-4 had a significantly higher prevalence of
cutaneous manifestations as compared to individuals infected with
any of the other DENV serotypes in this study. Furthermore, this
elevated prevalence in DENV-4 infection was observed for the
specific cutaneous findings of erythematous rash across all
locations (facial, central, or distal) as well as maculopapular rash,
all of which are unreported findings. A Taiwanese study of two
DENV serotypes found that those infected with DENV-3 were
more likely to have a rash than those infected with DENV-2
(51.6% vs 29.2%) [14], a trend we also found with those two
serotypes (14.6% vs 6.8%; p,0.01). A study from another
population in Peru noted a greater percentage of non-petechiael,
non-ecchymotic rash in participants infected with DENV-1
(23.1%) compared to DENV-2 (14.6%) or DENV-3 (7.1%) [16].
Our results also demonstrated a similar higher prevalence of these
manifestations in DENV-1 as compared to DENV-2 or DENV-3.
Neurological findings such as neck stiffness, impaired mental
status, focal motor deficits, and seizures have been described
primarily in individual reports or small case series and the majority
have been found to be associated with either DENV-2 or DENV-3
infection [15,33]. Although not statistically significant, we also
noted a higher proportion of neurological findings with DENV-2
and DENV-3.
This study has some limitations. First, our utilization of a clinic-
based passive surveillance system, compared with hospital-based
surveillance, most likely sampled patients with less severe disease.
Conversely, compared with home-visit-based active surveillance,
our study most likely recruited patients with more severe disease.
Such differences in sampling strategies are not necessarily a
weakness, but merit attention when considering the results.
Nevertheless, according to the Pan American Health Organiza-
tion, the annual ratio of DHF (or severe) cases to total dengue
cases in the four countries during the study period was extremely
low, most often numbering fewer than 1 in 500 [34]. Second, our
study was not designed to collect ancillary laboratory data (i.e.,
hematocrit, platelet count, and total protein) that would have
helped fulfill criteria for DHF classification [35]. For the reasons
outlined above, our study recruited only patients with dengue fever
and not DHF. While we did observe differences in certain clinical
manifestations by DENV serotype, we still cannot rule out the
possibility of underlying co-morbidities driving a particular
manifestation clustering within a DENV serotype. Last, given
the cross-sectional nature of this study, the differences in
prevalence of signs and symptoms by DENV serotype are purely
corollary, requiring additional, longitudinal studies to better assess
both the temporality of DENV infection with manifestation
occurrence as well as the specificity of the relationship.
While much of the research on signs and symptoms has focused
on the temporal order of DENV infection [8,36] or the unique
pathogenic role of DENV-2 [10,37] on outcomes such as DHF,
this is one of the first studies to perform a comprehensive
evaluation of clinical manifestations across all four DENV
serotypes in the Americas. The use of a highly specific laboratory
assay such as IFA to detect and serotype every DENV in
conjunction with standardized reporting and collection of clinical
information across a number of geographically diverse settings in
South America limits the potential for misclassification and other
potential biases. Our results indicate that specific individual
manifestations, as well as certain manifestation groups, were often
over-represented by a specific DENV serotype, emphasizing the
need to consider infection with each serotype as a distinct clinical
entity. More large-scale cross-sectional studies, as well as
longitudinal studies associating the temporal order of serotype-
specific DENV infection and the development of clinical
manifestations, are needed to confirm some of the novel findings
of this study. In addition, future studies concentrating on clinical
differences within serotypes (e.g., genotypes and lineages of a
certain serotype) will further elucidate the role between individual
DENV serotypes and morbidity.
Supporting Information
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